Quick Facts

Chemical Name
Tirzepatide
Also Known As
Mounjaro, Zepbound
Category
Metabolic & Weight Loss
Administration
Once-weekly subcutaneous injection

What is Tirzepatide?

Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By targeting both incretin pathways simultaneously, it produces greater effects than GLP-1 agonists alone. The SURMOUNT trials demonstrated unprecedented weight loss averaging 20-25% of body weight. FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, tirzepatide represents the cutting edge of metabolic peptide medicine.

How Does Tirzepatide Work?

Tirzepatide activates both GIP and GLP-1 receptors. While GLP-1 effects include increased insulin, decreased glucagon, slowed gastric emptying, and reduced appetite, GIP activation adds complementary metabolic benefits. GIP enhances the insulin response and may have direct effects on fat tissue, potentially explaining the greater efficacy. The dual activation produces synergistic effects on glucose control, weight loss, and potentially cardiovascular protection. The molecule is modified for once-weekly dosing.

Research-Backed Benefits

Superior Weight Loss

Strong Evidence

Up to 25% body weight reduction in trials, exceeding all other approved medications.

Excellent Glucose Control

Strong Evidence

HbA1c reductions of 2%+ in diabetes trials, superior to GLP-1 agonists alone.

Dual Mechanism

Strong Evidence

Activates both GIP and GLP-1 pathways for synergistic metabolic effects.

Cardiovascular Benefits

Emerging Research

SURPASS-CVOT trial ongoing; expected cardioprotection based on metabolic improvements.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
2.5 mg starting, titrated to 5-15 mg weekly
Frequency
Once weekly subcutaneous injection
Duration
Ongoing for weight maintenance

Must titrate slowly over several months. Start at 2.5mg for 4 weeks, then increase monthly by 2.5mg increments.

Side Effects & Safety

  • Nausea (common, usually transient)
  • Diarrhea
  • Vomiting
  • Constipation
  • Injection site reactions
  • Potential gallbladder issues
  • Similar theoretical concerns as GLP-1 agonists

Frequently Asked Questions

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide only activates GLP-1. This dual action produces greater weight loss (20-25% vs 15%) and possibly better glucose control.
The addition of GIP receptor activation appears to provide metabolic benefits beyond GLP-1 alone. GIP may have direct effects on fat tissue and enhance the overall metabolic response.
It's FDA-approved with extensive clinical trial data. Side effect profile is similar to GLP-1 agonists. Long-term safety data is still accumulating.
Weight loss begins within the first month but continues for 12-18 months. The slow titration means full dose isn't reached for 4-5 months, with peak effects continuing to develop after that.

References

  1. Jastreboff AM, et al. "SURMOUNT-1 tirzepatide weight loss." NEJM, 2022. PMID: 35658024
  2. Rosenstock J, et al. "SURPASS tirzepatide diabetes." NEJM, 2021. PMID: 33882225

Get the Complete Tirzepatide Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research